Trial NCT01117987

View at ClinicalTrials.gov 
Org. Study IDs: CQTI571A2301E1
Secondary IDs: 2009-018167-26

Last trial update was posted on 2015-08-13

MeSH Interventions

Imatinib Mesylate

MeSH Conditions

Familial Primary Pulmonary Hypertension Hypertension Pulmonary Arterial Hypertension

Other Conditions


Stopping Reasons

Novartis discontinued the development of imatinib in PAH due to requirement of regulatory authorities for additional data to secure marketing approval in PAH.

Limitations And Caveats

Within primary outcome measure (OM) #1, an additional death (>30 days post study completion) was included in the imatinib arm. The participant flow and secondary OM #2 reflect deaths that occurred up to and including 30 days post study completion.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID